Search research articles
Contact Us
Filters
Showing results (451-460 of 560) with videos related to
Page
of 56
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 6, 2008
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features
Lori J Goldstein, Robert Gray, Sunil Badve, et al.
Frontiers in Oncology
|
July 3, 2020
Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer
Douglas K Marks, Robyn D Gartrell, Margueritta El Asmar, et al.
Breast Cancer Research and Treatment
|
February 2, 2018
Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies
E Rakovitch, R Gray, F L Baehner, et al.
Breast Cancer Research and Treatment
|
April 14, 2021
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)
Tufia C Haddad, Jun He, Ciara C O'Sullivan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 9, 2009
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer
Joseph A Sparano, Stacy Moulder, Aslamuzzaman Kazi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2011
Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer
Joseph A Sparano, Lori J Goldstein, Barrett H Childs, et al.
ESMO Open
|
September 11, 2020
Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer
Morena Fasano, Carminia Maria Della Corte, Raimondo Di Liello, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2025
Machine Learning-Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2- Early Breast Cancer Using Real-World and NATALEE Data
Frederick M Howard, Peter A Fasching, Cesar A Santa-Maria, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2009
Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study
Joseph A Sparano, Anatoly N Makhson, Vladimir F Semiglazov, et al.
Cell Reports
|
December 2, 2014
Structure and cancer immunotherapy of the B7 family member B7x
Hyungjun Jeon, Vladimir Vigdorovich, Sarah C Garrett-Thomson, et al.
Page
of 56
Search research articles
Search
Showing results (451-460 of 560) with videos related to
Sort By:
Page
of 56
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 6, 2008
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features
Lori J Goldstein, Robert Gray, Sunil Badve, et al.
Frontiers in Oncology
|
July 3, 2020
Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer
Douglas K Marks, Robyn D Gartrell, Margueritta El Asmar, et al.
Breast Cancer Research and Treatment
|
February 2, 2018
Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies
E Rakovitch, R Gray, F L Baehner, et al.
Breast Cancer Research and Treatment
|
April 14, 2021
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)
Tufia C Haddad, Jun He, Ciara C O'Sullivan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 9, 2009
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer
Joseph A Sparano, Stacy Moulder, Aslamuzzaman Kazi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2011
Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer
Joseph A Sparano, Lori J Goldstein, Barrett H Childs, et al.
ESMO Open
|
September 11, 2020
Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer
Morena Fasano, Carminia Maria Della Corte, Raimondo Di Liello, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2025
Machine Learning-Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2- Early Breast Cancer Using Real-World and NATALEE Data
Frederick M Howard, Peter A Fasching, Cesar A Santa-Maria, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2009
Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study
Joseph A Sparano, Anatoly N Makhson, Vladimir F Semiglazov, et al.
Cell Reports
|
December 2, 2014
Structure and cancer immunotherapy of the B7 family member B7x
Hyungjun Jeon, Vladimir Vigdorovich, Sarah C Garrett-Thomson, et al.
Page
of 56